Pulmatrix Inc PULM:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 11:58 AM EDT
2.13quote price arrow up+0.04 (+2.15%)
Volume
5,246
52 week range
1.55 - 3.14
Loading...
  • Open2.08
  • Day High2.19
  • Day Low2.08
  • Prev Close2.09
  • 52 Week High3.14
  • 52 Week High Date05/03/23
  • 52 Week Low1.55
  • 52 Week Low Date03/19/24

Key Stats

  • Market Cap7.798M
  • Shares Out3.65M
  • 10 Day Average Volume0.03M
  • Dividend-
  • Dividend Yield-
  • Beta0.88
  • YTD % Change17.74

KEY STATS

  • Open2.08
  • Day High2.19
  • Day Low2.08
  • Prev Close2.09
  • 52 Week High3.14
  • 52 Week High Date05/03/23
  • 52 Week Low1.55
  • 52 Week Low Date03/19/24
  • Market Cap7.798M
  • Shares Out3.65M
  • 10 Day Average Volume0.03M
  • Dividend-
  • Dividend Yield-
  • Beta0.88
  • YTD % Change17.74

RATIOS/PROFITABILITY

  • EPS (TTM)-3.87
  • P/E (TTM)-0.55
  • Fwd P/E (NTM)-2.05
  • EBITDA (TTM)-14.606M
  • ROE (TTM)-57.51%
  • Revenue (TTM)7.298M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-193.49%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date05/10/2024
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Pulmatrix Inc

 

Profile

MORE
Pulmatrix, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of novel inhaled therapeutic products intended to prevent and treat respiratory and other diseases with important unmet medical needs using its patented iSPERSE technology. The Company’s proprietary product pipeline includes treatments for central nervous system (CNS) disorders, such as acute migraine and serious lung diseases, such as chronic obstructive pulmonary disease...
Michael Higgins
Independent Chairman of the Board
Teofilo Raad
President, Chief Executive Officer, Director
Peter Ludlum CPA
Interim Chief Financial Officer
Michelle Siegert
Vice President - Finance
Address
36 Crosby Drive, Suite 100
Bedford, MA
01730
United States